VCAM-1 as an Endothelial Factor for Diagnosis of Dementa in Parkinson’s Disease Ahmad Sobhani 1 , Homa Ebrahimi 1* , Ali Ebrahimi 1 , Mohammad Saadatnia 2 , Heshmatallah Orooji 1 and Ahmad Chitsaz 2 1 Clinical Research Development Center, Najaf Abad Branch, Islamic Azad University, Najaf Abad, Iran 2 Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran * Corresponding author: Homa Ebrahimi, Clinical Research Development Center, Najaf Abad Branch, Islamic Azad University, Najaf Abad, Iran, Tel: +989137124721, Fax: +989131040350; E-mail: h.ebrahimi66@yahoo.com Rec Date: July 25, 2017; Acc Date: January 22, 2018; Pub Date: January 27, 2018 Citaton: Sobhani A, Ebrahimi H, Ebrahimi A, Saadatnia M, Orooji H, et al. (2018) VCAM-1 as an Endothelial Factor for Diagnosis of Dementa in Parkinson's Disease. J Neurol Neurosci Vol.9 No.1:238. Abstract Background: Cognitve changes are ofen reported in Parkinson’s disease (PD). Numerous studies showed that there are changes in the paterns of infammaton when vascular dementa progressed, but the role of infammaton in PD is unknown. Methods: 75 consecutve diagnosed PD patents included. Patents divided into idiopathic PD (n=55) and PDD (n=20) based on DSM–IV criteria for diagnosis of dementa. Serum levels of vascular and infammatory biomarkers for interleukin-6 (IL-6), high sensitvity-C reactve protein (hs- CRP), soluble intracellular cell adhesion molecule (ICAM-1), soluble vascular cell adhesion molecule (VCAM-1) investgated by ELISA assay and compared between PD and PDD. Result: The signifcant enhancement of the VCAM-1 only found in serum of PDD compared to PD (56/06 ± 58/16 ng/ml vs. 30/43 ± 38/30, P=0/04), even afer adjustment age, gender and hypertension (OR=1/01, P=0/05). Cut-of point of VCAM-1 levels was equal to or greater than as 40/14 ng/ml for diferentatng dementa in PD from PD without dementa with sensitvity and specifcity were 73%, 64%. Conclusion: PDD patents had signifcant higher levels of VCAM-1 than PD, suggestng the serum levels of VCAM-1 may be a useful marker for PDD diagnosis. Future studies are needed to investgate possible associaton betweenVCAM-1 levels in PDD in larger sample size. Keywords: Dementa; Neurodegeneratve disorders; Cognitve; Elisa; Biomarkers; Parkinson's disease; DSM-IV Introducton Dementa in neurodegeneratve disorders such as Parkinson’s disease (PD) was as an impairment in the structure and functon of cerebral blood vessels and associated cells (neurovascular unit), and these efects are mediated by infammaton [1]. Systemic and central immune systems can communicate in the presence of an intact brain blood barrier (BBB). In AD (Alzheimer’s disease), where there is evidence of a breakdown in BBB permeability [2-5], there is an even greater likelihood of communicaton by means of infammatory mediators between the CNS and periphery. Some studies showed that plasma levels of infammatory markers such as Interleukin-6 (IL-6) and high sensitvity Creatve protein (hs-CRP) increased in the early stages of PD and in the early stages of Cognitve decline leading to AD [6]. Recently there is an actvated research feld to an early role for infammatory processes in disease onset and progression, accumulatng research also focuses a more complicated picture, in which pro-infammatory markers inconsistently and at tmes inversely relate to cognitve decline. Several large comprehensive studies declared no associaton between baseline infammaton and future risk of AD or non-AD dementa or have noted no independent efects over and above traditonal vascular risk factors [7-9]. Due to the actvated primary response of immune system, it has been observed that endothelial dysfuncton markers such as soluble inter-cellular adhesion molecule (ICAM-1) and soluble vascular cell adhesion molecule (VCAM-1) increased in neurodegeneratve disease [10]. However, other studies have reported no associaton [11,12] in identfying the diagnostc biomarker in dementa in Parkinson's patents help clinician that select right patents for appropriate treatment. The Present study designed to answer the queston whether the infammatory biomarkers have a suitable power in comparing to vascular biomarkers for diagnosis of dementa in PD, so, we investgate the serum concentraton of hs-CRP and IL-6 as representatve of systemic infammaton and ICAM-1 and VCAM-1 as vascular biomarkers. Research Article iMedPub Journals www.imedpub.com DOI: 10.21767/2171-6625.1000243 Journal of Neurology and Neuroscience ISSN 2171-6625 Vol.9 No.1:243 2018 © Copyright iMedPub | This article is available from: 10.21767/2171-6625.1000243 1